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Sir,
We wish to address the recent proposal of a disease entity
newly titled ‘limbic-predominant age-related TDP-43 ence-
phalopathy (LATE)’ (Nelson et al., 2019) which, to our
reading, is itself a derivative of the 2016 proposed term
cerebral age-related TDP-43 with sclerosis (CART)
(Nelson et al., 2016). The transactive response DNA
binding protein of 43 kD (TDP-43) was ﬁrst reported
in 2006 to be a main component of ubiquitinated inclu-
sions in autopsy-conﬁrmed cases of frontotemporal lobar
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degeneration (FTLD) negative for tau immunoreactivity
(Arai et al., 2006; Neumann et al., 2006). Over a decade
of research into FTLD-TDP (and FTLD-U before it) has
highlighted important phenotypic variability in TDP-43-
immunoreactive lesions resulting in the identiﬁcation of
ﬁve different types of FTLD-TDP (Mackenzie et al., 2006,
2011; Sampathu et al., 2006; Josephs et al., 2009; Lee
et al., 2011, 2017). There have also been important
advances in the molecular and biochemical characterization
of TDP-immunoreactive in FTLD-TDP (Sampathu et al.,
2006; Hasegawa et al., 2008; Igaz et al., 2008; Zhang
et al., 2009; Bigio et al., 2013; Laferriere et al., 2019).
Soon after the initial characterization of TDP-immunoreac-
tive lesions in FTLD and amyotrophic lateral sclerosis,
TDP-immunoreactive lesions were identiﬁed in 25–33%
of cases with pathologically conﬁrmed Alzheimer’s disease
(Amador-Ortiz et al., 2007; Higashi et al., 2007). TDP-
immunoreactive lesions related to Alzheimer’s disease
were initially thought to appear ﬁrst in the hippocampus
(Amador-Ortiz et al., 2007), but more detailed morpholo-
gical studies involving multiple anatomical regions revealed
the amygdala to be the earliest affected region (Higashi
et al., 2007; Hu et al., 2008; Arai et al., 2009) followed
by the entorhinal cortex and hippocampus, occipitotem-
poral cortex, insular and inferior temporal cortex, brain-
stem, and frontal neocortex and basal ganglia (Josephs
et al., 2014, 2016); a scheme that has been independently
validated (Tan et al., 2015). TDP-immunoreactive lesions
have also been described in cognitively normal individuals
(Wilson et al., 2011; Arnold et al., 2013; Uchino et al.,
2015; Wennberg et al., 2019) including those with asymp-
tomatic deﬁnite primary age related tauopathy (PART)
(Josephs et al., 2017; Zhang et al., 2019), as well being
associated with other well-deﬁned clinic-pathological enti-
ties (Fig. 1) including Lewy body disease (with or without
co-existing Alzheimer’s disease) (Arai et al., 2009;
McAleese et al., 2017), the amyotrophic lateral sclerosis/
parkinsonism-dementia complex of Guam (Hasegawa
et al., 2007; Geser et al., 2008), Pick’s disease (Freeman
et al., 2008), progressive supranuclear palsy (Yokota et al.,
2010; Koga et al., 2017), corticobasal degeneration (Uryu
et al., 2008; Koga et al., 2018), polyglutamine diseases
such as Huntington’s disease (Schwab et al., 2008),
Machado-Joseph disease (Tan et al., 2009) and spinocere-
bellar ataxia type 2 (Toyoshima et al., 2011), Perry syn-
drome (Wider et al., 2009), and chronic traumatic
encephalopathy (McKee et al., 2010).
The term LATE is proposed as a catchy acronym to
describe the presence of TDP-immunoreactive lesions in
Alzheimer’s disease, as well as in older adults. The review
manuscript describing LATE, of which many of the authors
of this response are cited in, provides a thorough appraisal
of an important topic and is meritorious in promoting
recognition of TDP-43 and encouraging future research,
as well as the development of neuroimaging and molecular
biomarkers. However, we question the term’s novelty and
nosology, the framework that seemingly separates LATE
from FTLD-TDP and other diseases, and the proposed
guidelines provided for assessing LATE and LATE-NC.
As the authors identify, the term LATE is new, although
there is an extensive literature on the relationship between
TDP-immunoreactive inclusions and clinical and imaging
features, both in isolation and in association with
Alzheimer’s disease. LATE is used to rebrand already char-
acterized features, yet identiﬁes no new TDP-43 pathologi-
cal subtype, no link between TDP-immunoreactive
pathology with new cognitive symptoms (other than like-
lihood of dementia diagnosis) according to known brain–
behaviour relationship, and no biochemical demonstration
that TDP-immunoreactive lesions in older adults with and
without Alzheimer’s disease are equivalent to each other or
distinct from those in FTLD-TDP and other neurodegen-
erative diseases. Critically, using the term encephalopathy
(‘E’ of LATE) presumes causation of functional impairment
Figure 1 TDP-43 immunoreactive inclusions can be found in many different neurodegenerative diseases. Currently TDP-43
proteinopathies are divided into primary TDP-43 proteinopathies and mixed (secondary) TDP-43 proteinopathies. AD = Alzheimer’s disease;
ALS = amyotrophic lateral sclerosis; CBD = corticobasal degeneration; CTE = chronic traumatic encephalopathy; FTLD = frontotemporal lobar
degeneration; LBD = Lewy body disease; PART = primary age related tauopathy; PDC = Parkinson-dementia complex; PSP = progressive supra-
nuclear palsy; SCA = spinocerebellar ataxia.
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in the cerebrum and by incorporating the term encephalo-
pathy, LATE implies a clinicopathological entity, when in
reality LATE is only describing the pathology LATE-NC;
similar to pathologies such as argyrophilic grains disease
(Braak and Braak, 1987), primary age-related tauopathy
(Crary et al., 2014), ageing-related tau astrogliopathy
(Kovacs et al., 2016) and amygdala Lewy bodies
(Uchikado et al., 2006), which are not considered clinico-
pathological entities. Akin to the dichotomy of language
between frontotemporal dementia and FTLD, LATE is
something that, by deﬁnition, cannot be diagnosed under
the microscope (i.e. encephalopathy). And as these lesions
can be observed in the absence of cognitive alterations,
rendering a diagnosis of an encephalopathy in a cognitively
normal individual is an oxymoron (normal cognition with
limbic associated TDP-43 encephalopathy).
Proposing that LATE is a distinct clinicopathological
entity also overlooks the possibility that TDP-immunoreac-
tive lesions in Alzheimer’s disease could reﬂect impaired
cellular function in end-stage neurodegeneration, and
ignores the fact that the statistical association between
TDP-immunoreactive pathology and a dementia diagnosis
in old age is likely both not independent from Alzheimer’s
disease and other pathologies, and, in all likelihood, a
reﬂection of competing relative risks of various degrees as
one ages. In addition, the term limbic-predominant is an
over simpliﬁcation of the distribution of pathology. In fact,
it has been demonstrated that there are different subtypes
of TDP immunoreactivity that have different regional asso-
ciations, with only one speciﬁc subtype of neuroﬁbrillary
tangle-associated TDP proving to be truly limbic-predomi-
nant (Amador-Ortiz et al., 2007; Josephs et al., 2019;
Zhang et al., 2019). The other subtype is associated with
TDP-43 involving cortical and subcortical and brainstem
regions identical to those affected in FTLD-TDP (Josephs
et al., 2019). This is akin to Lewy body disease, which can
also have a limbic-predominance, but to label it as such
would ignore the brainstem and diffuse distributions of
the pathology. Different subtypes of TDP-immunoreactive
also have different genetic and pathological associations,
including with hippocampal sclerosis; important differences
that would be lost when grouping subtypes together
(Murray et al., 2014; Josephs et al., 2019).
Third, this paper does not consider how LATE can be
distinguished from FTLD-TDP or the fact that LATE
depends on a relative selection bias towards Alzheimer’s
disease-related diseases while ignoring the fact that TDP-
43 has been identiﬁed in many other neurodegenerative
diseases (Fig. 1) making teasing apart coincident versus
associated processes a challenge. Of importance is the fact
that a proportion of cases of Alzheimer’s disease and
ageing have TDP-immunoreactive lesions present in fronto-
temporal neocortex (Arai et al., 2009; Josephs et al., 2014,
2016; Nag et al., 2018). It has been shown that such cases
are strongly associated with single nucleotide polymorph-
isms in the TMEM106B gene (Josephs et al., 2019), which
is similar to the observed associations in FTLD-TDP (Van
Deerlin et al., 2010). It is, therefore, unclear whether it is
appropriate to make a diagnosis of LATE in the presence of
a TDP-43 stage 43 (Josephs et al., 2014, 2016), as
opposed to a diagnosis of FTLD-TDP. The description of
LATE also does not square with evidence that FTLD-TDP
can occur in old age (Jellinger, 2006; Pao et al., 2011), and
that age itself may modify the clinical phenomenology of
neuropathology due to the brain’s structural and functional
reorganization.
The authors provide guidelines on how to assess LATE-
NC neuropathologically and suggest analysing a few speci-
ﬁc regions of the brain with the intent to have a limited
number of TDP-43 stages. While this simpliﬁes neuro-
pathological analysis and is touted as being cost effective,
it collapses data-driven staging schemes but without the
requisite scientiﬁc evidence for doing so. This proposal mir-
rors the NIA-AA neuropathological guidelines for the
pathological diagnosis of Alzheimer’s disease, which col-
lapse the Braak (Braak and Braak, 1991), Thal (Thal
et al., 2002) and CERAD (Mirra et al., 1991) staging
schemes. However, collapsing the TDP-43 staging scheme
at such an early point in time when it was only published
in the past few years, stiﬂes the ﬁelds ability to understand
the implications of the distribution of TDP-43 deposition
and goes against the drive by many neuropathologists to
include more comprehensive and quantitative assessment
methods to unravel currently hidden relationships of
pathologies.
The branding of clinical trials since the 1990s—especially
names such as EPIC or EXCITE—is said to promote refer-
ence to such trials (Berkwits, 2000), but can compete with
the understanding of the main message (Berlin, 2013;
Narod et al., 2016; Witteman et al., 2018). Whether an
acronym such is LATE is needed for diagnostic accuracy
and communication between neuropathologists, neurolo-
gists, and other investigators is not clear. Therefore, we
urge researchers to focus on deﬁning the pathological pro-
cesses and their biochemical differences underlying TDP-
immunoreactive lesions in FTLD and non-FTLD disorders,
particularly in diverse populations, and defer broad usage
of LATE until (and only if) the science is mature.
Data availability
Data sharing is not applicable to this article as no new data
were created or analysed in this study.
Competing interests
The authors report no competing interests.
References
Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R,
et al. TDP-43 immunoreactivity in hippocampal sclerosis and
Alzheimer’s disease. Ann Neurol 2007; 61: 435–45.
Letter to the Editor BRAIN 2019: 0; 1–5 | e3
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
z224/5540355 by U
C
L, London user on 13 August 2019
Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al.
TDP-43 is a component of ubiquitin-positive tau-negative inclusions
in frontotemporal lobar degeneration and amyotrophic lateral scler-
osis. Biochem Biophys Res Commun 2006; 351: 602–11.
Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K,
Tsuchiya K, et al. Phosphorylated TDP-43 in Alzheimer’s disease
and dementia with Lewy bodies. Acta Neuropathol 2009; 117:
125–36.
Arnold SJ, Dugger BN, Beach TG. TDP-43 deposition in prospectively
followed, cognitively normal elderly individuals: correlation with
argyrophilic grains but not other concomitant pathologies. Acta
Neuropathol 2013; 126: 51–7.
Berkwits M. Capture! Shock! Excite! Clinical trial acronyms and the
“branding” of clinical research. Ann Intern Med 2000; 133: 755–
62.
Berlin L. TAC: AOITROMJA? (the acronym conundrum: advancing
or impeding the readability of medical journal articles?). Radiology
2013; 266: 383–7.
Bigio EH, Wu JY, Deng HX, Bit-Ivan EN, Mao Q, Ganti R, et al.
Inclusions in frontotemporal lobar degeneration with TDP-43 pro-
teinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but
not FTLD with FUS proteinopathy (FTLD-FUS), have properties of
amyloid. Acta Neuropathol 2013; 125: 463–5.
Braak H, Braak E. Argyrophilic grains: characteristic pathology of
cerebral cortex in cases of adult onset dementia without Alzheimer
changes. Neurosci Lett 1987; 76: 124–7.
Braak H, Braak E. Neuropathological staging of Alzheimer-related
changes. Acta Neuropathol 1991; 82: 239–59.
Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL,
Alafuzoff I, et al. Primary age-related tauopathy (PART): a common
pathology associated with human aging. Acta Neuropathol 2014;
128: 755–66.
Freeman SH, Spires-Jones T, Hyman BT, Growdon JH, Frosch MP.
TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp
Neurol 2008; 67: 62–7.
Geser F, Winton MJ, Kwong LK, Xu Y, Xie SX, Igaz LM, et al.
Pathological TDP-43 in parkinsonism-dementia complex and amyo-
trophic lateral sclerosis of Guam. Acta Neuropathol 2008; 115:
133–45.
Hasegawa M, Arai T, Akiyama H, Nonaka T, Mori H, Hashimoto T,
et al. TDP-43 is deposited in the Guam Parkinsonism-dementia com-
plex brains. Brain 2007; 130: 1386–94.
Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume
Y, et al. Phosphorylated TDP-43 in frontotemporal lobar degener-
ation and amyotrophic lateral sclerosis. Ann Neurol 2008; 64: 60–
70.
Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K,
et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in
brains of Alzheimer’s disease and dementia with Lewy bodies. Brain
Res 2007; 1184: 284–94.
Hu WT, Josephs KA, Knopman DS, Boeve BF, Dickson DW, Petersen
RC, et al. Temporal lobar predominance of TDP-43 neuronal cyto-
plasmic inclusions in Alzheimer disease. Acta Neuropathol 2008;
116: 215–20.
Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, et al.
Enrichment of C-terminal fragments in TAR DNA-binding protein-
43 cytoplasmic inclusions in brain but not in spinal cord of fronto-
temporal lobar degeneration and amyotrophic lateral sclerosis. Am J
Pathol 2008; 173: 182–94.
Jellinger KA. Clinicopathological analysis of dementia disorders in the
elderly: an update. J Alzheimers Dis 2006; 9: 61–70.
Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM,
Perkerson RB, et al. Pathological, imaging and genetic characteristics
support the existence of distinct TDP-43 types in non-FTLD brains.
Acta Neuropathol 2019; 137: 227–38.
Josephs KA, Murray ME, Tosakulwong N, Whitwell JL, Knopman
DS, Machulda MM, et al. Tau aggregation inﬂuences cognition
and hippocampal atrophy in the absence of beta-amyloid: a
clinico-imaging-pathological study of primary age-related tauopathy
(PART). Acta Neuropathol 2017; 133: 705–15.
Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack
CR, et al. Staging TDP-43 pathology in Alzheimer’s disease. Acta
Neuropathol 2014; 127: 441–50.
Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD,
Petrucelli L, et al. Updated TDP-43 in Alzheimer’s disease staging
scheme. Acta Neuropathol 2016; 131: 571–85.
Josephs KA, Stroh A, Dugger B, Dickson DW. Evaluation of subcor-
tical pathology and clinical correlations in FTLD-U subtypes. Acta
Neuropathol 2009; 118: 349–58.
Koga S, Kouri N, Walton RL, Ebbert MTW, Josephs KA, Litvan I,
et al. Corticobasal degeneration with TDP-43 pathology presenting
with progressive supranuclear palsy syndrome: a distinct clinico-
pathologic subtype. Acta Neuropathol 2018; 136: 389–404.
Koga S, Sanchez-Contreras M, Josephs KA, Uitti RJ, Graff-Radford N,
van Gerpen JA, et al. Distribution and characteristics of transactive
response DNA binding protein 43 kDa pathology in progressive
supranuclear palsy. Mov Disord 2017; 32: 246–55.
Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H,
et al. Aging-related tau astrogliopathy (ARTAG): harmonized evalu-
ation strategy. Acta Neuropathol 2016; 131: 87–102.
Laferriere F, Maniecka Z, Perez-Berlanga M, Hruska-Plochan M,
Gilhespy L, Hock EM, et al. TDP-43 extracted from frontotemporal
lobar degeneration subject brains displays distinct aggregate assem-
blies and neurotoxic effects reﬂecting disease progression rates. Nat
Neurosci 2019; 22: 65–77.
Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mech-
anisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci
2011; 13: 38–50.
Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK, et al.
Expansion of the classiﬁcation of FTLD-TDP: distinct pathology
associated with rapidly progressive frontotemporal degeneration.
Acta Neuropathol 2017; 134: 65–78.
Mackenzie IR, Baborie A, Pickering-Brown S, Du Plessis D, Jaros E,
Perry RH, et al. Heterogeneity of ubiquitin pathology in frontotem-
poral lobar degeneration: classiﬁcation and relation to clinical
phenotype. Acta Neuropathol 2006; 112: 539–49.
Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D,
Jaros E, et al. A harmonized classiﬁcation system for FTLD-TDP
pathology. Acta Neuropathol 2011; 122: 111–3.
McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems
J. TDP-43 pathology in Alzheimer’s disease, dementia with Lewy
bodies and ageing. Brain Pathol 2017; 27: 472–9.
McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall
NW, et al. TDP-43 proteinopathy and motor neuron disease in
chronic traumatic encephalopathy. J Neuropathol Exp Neurol
2010; 69: 918–29.
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM,
et al. The Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD). Part II. Standardization of the neuropathologic
assessment of Alzheimer’s disease. Neurology 1991; 41: 479–86.
Murray ME, Cannon A, Graff-Radford NR, Liesinger AM,
Rutherford NJ, Ross OA, et al. Differential clinicopathologic and
genetic features of late-onset amnestic dementias. Acta Neuropathol
2014; 128: 411–21.
Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA. TDP-
43 pathology in anterior temporal pole cortex in aging and
Alzheimer’s disease. Acta Neuropathol Commun 2018; 6: 33.
Narod SA, Ahmed H, Akbari MR. Do acronyms belong in the medical
literature? A countercurrents series. Curr Oncol 2016; 23: 295–6.
Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle P, Arfanakis
K. Limbic-predominant age-related TDP-43 encephalopathy (LATE):
consensus working group report. Brain 2019; 142: 1503–27.
Nelson PT, Trojanowski JQ, Abner EL, Al-Janabi OM, Jicha GA,
Schmitt FA, et al. New old pathologies: AD, PART, and cerebral
age-related TDP-43 with sclerosis (CARTS). J Neuropathol Exp
Neurol 2016; 75: 482–98.
e4 | BRAIN 2019: 0; 1–5 Letter to the Editor
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
z224/5540355 by U
C
L, London user on 13 August 2019
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC,
Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar de-
generation and amyotrophic lateral sclerosis. Science 2006; 314:
130–3.
Pao WC, Dickson DW, Crook JE, Finch NA, Rademakers R, Graff-
Radford NR. Hippocampal sclerosis in the elderly: genetic and
pathologic ﬁndings, some mimicking Alzheimer disease clinically.
Alzheimer Dis Assoc Disord 2011; 25: 364–8.
Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M,
Truax A, et al. Pathological heterogeneity of frontotemporal lobar
degeneration with ubiquitin-positive inclusions delineated by ubiqui-
tin immunohistochemistry and novel monoclonal antibodies. Am J
Pathol 2006; 169: 1343–52.
Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of
transactivation-responsive DNA-binding protein 43 and huntingtin
in inclusions of Huntington disease. J Neuropathol Exp Neurol
2008; 67: 1159–65.
Tan RH, Kril JJ, Fatima M, McGeachie A, McCann H, Shepherd C,
et al. TDP-43 proteinopathies: pathological identiﬁcation of brain
regions differentiating clinical phenotypes. Brain 2015; 138: 3110–
22.
Tan CF, Yamada M, Toyoshima Y, Yokoseki A, Miki Y, Hoshi Y,
et al. Selective occurrence of TDP-43-immunoreactive inclusions in
the lower motor neurons in Machado-Joseph disease. Acta
Neuropathol 2009; 118: 553–60.
Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in
the human brain and its relevance for the development of AD.
Neurology 2002; 58: 1791–800.
Toyoshima Y, Tanaka H, Shimohata M, Kimura K, Morita T, Kakita
A, et al. Spinocerebellar ataxia type 2 (SCA2) is associated with
TDP-43 pathology. Acta Neuropathol 2011; 122: 375–8.
Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease
with amygdala Lewy bodies: a distinct form of alpha-synucleinopa-
thy. J Neuropathol Exp Neurol 2006; 65: 685–97.
Uchino A, Takao M, Hatsuta H, Sumikura H, Nakano Y, Nogami A,
et al. Incidence and extent of TDP-43 accumulation in aging human
brain. Acta Neuropathol Commun 2015; 3: 35.
Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM,
Grossman M, et al. Concomitant TAR-DNA-binding protein 43 path-
ology is present in Alzheimer disease and corticobasal degeneration but
not in other tauopathies. J Neuropathol Exp Neurol 2008; 67: 555–64.
Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A,
Wang LS, Graff-Radford NR, et al. Common variants at 7p21 are
associated with frontotemporal lobar degeneration with TDP-43 in-
clusions. Nat Genet 2010; 42: 234–9.
Wennberg AM, Whitwell JL, Tosakulwong N, Weigand SD, Murray
ME, Machulda MM, et al. The inﬂuence of tau, amyloid, alpha-
synuclein, TDP-43, and vascular pathology in clinically normal eld-
erly individuals. Neurobiol Aging 2019; 77: 26–36.
Wider C, Dickson DW, Stoessl AJ, Tsuboi Y, Chapon F, Gutmann L,
et al. Pallidonigral TDP-43 pathology in Perry syndrome.
Parkinsonism Relat Disord 2009; 15: 281–6.
Wilson AC, Dugger BN, Dickson DW, Wang DS. TDP-43 in aging and
Alzheimer’s disease: a review. Int J Clin Exp Pathol 2011; 4: 147–55.
Witteman HO, Chipenda Dansokho S, Colquhoun H, Fagerlin A,
Giguere AMC, Glouberman S, et al. Twelve lessons learned for ef-
fective research partnerships between patients, caregivers, clinicians,
academic researchers, and other stakeholders. J Gen Intern Med
2018; 33: 558–62.
Yokota O, Davidson Y, Bigio EH, Ishizu H, Terada S, Arai T, et al.
Phosphorylated TDP-43 pathology and hippocampal sclerosis in pro-
gressive supranuclear palsy. Acta Neuropathol 2010; 120: 55–66.
Zhang X, Sun B, Wang X, Lu H, Shao F, Rozemuller AJM, et al.
Phosphorylated TDP-43 staging of primary age-related tauopathy.
Neurosci Bull 2019; 35: 183–92.
Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, et al.
Aberrant cleavage of TDP-43 enhances aggregation and cellular tox-
icity. Proc Natl Acad Sci U S A 2009; 106: 7607–12.
Letter to the Editor BRAIN 2019: 0; 1–5 | e5
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
z224/5540355 by U
C
L, London user on 13 August 2019
